Dinara Ilyasova

Dr. Dinara Ilyasova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
IRIgor Reshetov
Igor Reshetov
AAAnna Alyasova
Anna Alyasova
OSOlga Shpileva
Olga Shpileva
PKPavel Karalkin
Pavel Karalkin
KEKanamat Efendiev
Kanamat Efendiev
ASArtem Shiryaev
Artem Shiryaev
Background: Photodynamic therapy (PDT) has emerged as a powerful minimally invasive modality for cancer treatment. However, its efficacy as a monotherapy is often limited by oxygen dependence and limited light penetration. Combining PDT with systemic anticancer drug therapies offers a promising strategy to achieve synergistic effects and overcome resistance. Objective: This review aims to provide a systematic analysis of the mechanisms and clinical potential of combining PDT with chemotherapy, targeted therapy, and immunotherapy, focusing on recent advancements and nanotechnology-based delivery systems. Methods: A comprehensive literature search was performed using PubMed and Scopus databases. The analysis focused on peer-reviewed studies published over the last 10 years addressing synergistic molecular pathways, co-delivery nanoplatforms, and clinical trial outcomes. Results: The combination of PDT with chemotherapy enhances drug accumulation via vascular photosensitization and can overcome multi-drug resistance. Integration with immunotherapy, particularly immune checkpoint inhibitors and tumor vaccines, triggers immunogenic cell death (ICD), leading to systemic antitumor responses. Nanotechnology provides a versatile platform for the targeted co-delivery of photosensitizers and pharmacological agents, significantly reducing systemic toxicity. Conclusions: Combined PDT–drug regimens demonstrate superior therapeutic efficacy compared to monotherapies. Future clinical translation requires the standardization of dosimetry and the development of multifunctional nanomedicines to enable personalized treatment protocols.

Verified
Journal Article
Open access
PDF file
AAAnna Alyasova
Anna Alyasova
KEKanamat Efendiev
Kanamat Efendiev
IRIgor Reshetov
Igor Reshetov
DIDinara Ilyasova
Dinara Ilyasova
OSOlga Shpileva
Olga Shpileva
ASArtem Shiryaev
Artem Shiryaev
Peritoneal carcinomatosis (PC) is a common, prognostically unfavorable manifestation of advanced gastrointestinal and gynecological malignancies whose treatment is constrained by the blood-peritoneal barrier, which limits drug penetration even when cytoreductive surgery is combined with systemic chemotherapy. This review evaluates current intraperitoneal treatment modalities and emerging technologies for overcoming this limitation, based on recent clinical trials and meta-analyses identified through Scopus and PubMed. We sequentially examine conventional intraperitoneal chemotherapy (IPC); hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian, gastric, and colorectal cancers, with attention to patient selection and the peritoneal cancer index as determinants of survival benefit; pressurized intraperitoneal aerosol chemotherapy (PIPAC) and its electrostatic precipitation variant (ePIPAC); and photodynamic and photothermal therapy for tumor treatment. Novel strategies are also discussed, including IPC combined with immune checkpoint inhibitors, optical dosimetry, and nanomedicine-based drug delivery as tools for improving treatment precision. Overall, management of PC is transitioning toward a personalized, multimodal approach: HIPEC and PIPAC provide standardized platforms for regional therapy, but future progress depends on integrating advanced drug delivery systems, immunotherapy, and real-time intraoperative monitoring, with standardization of protocols through large multicenter trials remaining a priority for translating these modalities into clinical practice.

1 January 2025 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
AGAida Vladimirovna Gilyadova
Aida Vladimirovna Gilyadova
AIA.A. Ishchenko
A.A. Ishchenko
AIA.I. Ishchenko
A.I. Ishchenko
EKE.M. Kulikova
E.M. Kulikova
NPN.V. Petukhova
N.V. Petukhova
IRI.V. Reshetov
I.V. Reshetov
Endometrial cancer is one of the most common malignant neoplasms in female patients. Despite the latest advances in medicine, the incidence of this disease is increasing every year. The growing use of molecular and genetic profiling and immune checkpoint inhibitors is aimed at reducing morbidity, improving prognosis and survival outcomes, especially for patients with hypermutated mismatch repair deficiency/microsatellite instability and an ultra-mutated profile. Risk factors determined by histological examination include morphology, stage and degree of differentiation according to the FIGO classification, depth of myometrial invasion, and lymphovascular space invasion. They are useful to identify the need for postoperative treatment to reduce the risk of recurrence. Moreover, the leading factor influencing the prognosis of the disease is the involvement of lymph nodes in the malignant process. On the one hand, many retrospective studies have shown the positive effect of lymphadenectomy on recurrence-free survival in patients. On the other hand, this procedure may be followed by certain risks and complications, which casts doubt on the consideration of this treatment method as the gold standard for low-grade tumors. Additional data based on molecular and genomic characteristics of endometrial tumors are needed to assess the status of lymph nodes, and the inclusion of molecular classification in the traditional clinical and pathological staging system for endometrial cancer is becoming increasingly important and critical. Objective. To analyze literature data on the current state and assess the diagnostic significance of known molecular and genetic predictors in relation to the evaluation of the risk of endometrial cancer progression. Key words: uterine cancer, endometrioid adenocarcinoma, molecular predictors, genetic profiling, lymphadenectomy, microRNA, tumor marker